Share on LinkedInShare on LinkedIn

ARTICLE · 14 NOVEMBER 2020

Supreme Court Hears Oral Arguments On Affordable Care Act: Will Biosimilars Survive?

Today the Supreme Court heard arguments in Texas v. Azar that the Affordable Care Act (ACA)'s individual coverage mandate is unconstitutional.

United StatesLitigation, Mediation & Arbitration

Today the Supreme Court heard arguments in Texas v. Azar that the Affordable Care Act (ACA)'s individual coverage mandate is unconstitutional.  According to the ruling in the underlying case, in the absence of the individual mandate, the rest of the ACA cannot stand.

While the consequences of striking down the ACA are vast, it also includes putting the future of biosimilars in jeopardy.  By way of background, the Biologics Price Competition and Innovation Act (BPCIA), was passed as part of the ACA to allow for abbreviated biologics license applications to be filed for complex products which are biosimilar to/interchangeable with FDA-licensed biologics.

If the Supreme Court strikes down most — or all — of the ACA, the regulatory pathway for biosimilars would essentially disappear overnight.  This would affect millions of patients who would no longer see more affordable biosimilar versions of high-cost biologic treatments reach the market.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from